Los Angeles Capital Management LLC Has $1.27 Million Position in Organon & Co. (NYSE:OGN)

Los Angeles Capital Management LLC lowered its position in Organon & Co. (NYSE:OGN - Free Report) by 67.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 85,322 shares of the company's stock after selling 174,509 shares during the quarter. Los Angeles Capital Management LLC's holdings in Organon & Co. were worth $1,273,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Fisher Funds Management LTD bought a new position in Organon & Co. during the fourth quarter valued at about $1,897,000. Deseret Mutual Benefit Administrators boosted its holdings in Organon & Co. by 24.3% during the fourth quarter. Deseret Mutual Benefit Administrators now owns 6,256 shares of the company's stock valued at $93,000 after acquiring an additional 1,222 shares during the period. Hussman Strategic Advisors Inc. bought a new position in Organon & Co. in the 4th quarter worth approximately $2,820,000. Handelsbanken Fonder AB boosted its position in shares of Organon & Co. by 17.8% in the fourth quarter. Handelsbanken Fonder AB now owns 80,365 shares of the company's stock valued at $1,199,000 after acquiring an additional 12,115 shares during the period. Finally, Global Retirement Partners LLC grew its stake in shares of Organon & Co. by 730.9% in the fourth quarter. Global Retirement Partners LLC now owns 8,284 shares of the company's stock worth $124,000 after acquiring an additional 7,287 shares during the last quarter. 77.43% of the stock is owned by institutional investors and hedge funds.

Organon & Co. Price Performance

Shares of OGN stock traded up $0.16 during trading hours on Wednesday, hitting $14.45. The company had a trading volume of 2,912,428 shares, compared to its average volume of 2,304,003. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70. The firm has a market capitalization of $3.72 billion, a price-to-earnings ratio of 4.34, a PEG ratio of 0.90 and a beta of 0.76. Organon & Co. has a 12 month low of $13.87 and a 12 month high of $23.10. The firm's fifty day moving average is $15.42 and its 200 day moving average is $16.99.

Organon & Co. (NYSE:OGN - Get Free Report) last issued its earnings results on Thursday, February 13th. The company reported $0.83 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.09). Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. The firm had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.57 billion. On average, sell-side analysts predict that Organon & Co. will post 3.68 EPS for the current fiscal year.

Organon & Co. Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 13th. Shareholders of record on Monday, February 24th will be given a $0.28 dividend. The ex-dividend date is Monday, February 24th. This represents a $1.12 annualized dividend and a yield of 7.75%. Organon & Co.'s payout ratio is 33.63%.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. TD Cowen upgraded shares of Organon & Co. to a "hold" rating in a research note on Wednesday, January 15th. Barclays cut their price objective on shares of Organon & Co. from $26.00 to $24.00 and set an "overweight" rating for the company in a research report on Friday, February 14th. Finally, Morgan Stanley reduced their target price on shares of Organon & Co. from $17.00 to $16.00 and set an "equal weight" rating for the company in a research note on Friday, February 14th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Organon & Co. currently has a consensus rating of "Hold" and an average price target of $20.80.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.